Inve India ▾

Fischer Medical Ventures share price & results

Fischer Medical Ventures Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q2 FY26
Ownership as of
Sept 2026

Indian manufacturer of MRI/CT imaging systems (Time Medical) plus AI-enabled preventive-health screening kiosks (FlynnCare).

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue81.9 ₹ crore+249.5% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin13.7 %−3.3 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit3.8 ₹ crore−22.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity6.77 %+8.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin1.62 %+83.6 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)195.82 %−251.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

6 targets tracked, none judged yet · 6 open · verdicts reflect calls analysed to Q2 FY26.

Fischer Medical Ventures Limited management guidance track record on Inve: 6 targets tracked across analysed earnings calls (0 achieved, 0 missed, 6 open).

TargetOriginal wordingSaidLatest callVerdict
Market Share (Domestic & Asian MRI)15% to 20% market share domestically and in the Asian market
Call transcript, Q2 FY26 · 7 Nov 2025		Q2 FY26Q2 FY26:Target set by management based on current order book and demand.
Call transcript, Q2 FY26 · 7 Nov 2025		New

Source: Inve Guidance Tracker for Fischer Medical Ventures Limited · to Q2 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

6 of Fischer Medical Ventures Limited's 6 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 5 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹25.54 −5.41% · −₹1.46

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −75.5% 1Y

₹20₹40₹60₹80₹100₹120Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 7 Nov 2025

1Y: ₹104.17 on 24 Oct 2025 → ₹25.54. High ₹117.71 (31 Oct 2025), low ₹23.87 (22 Oct 2026).

Previous close
₹27
Market cap
₹1.9k Cr
52-week range
₹23.87 – ₹117.71
One year
−77.01%
Price to earnings (TTM to Jun 2026)
77.04×
Return on equity (TTM to Jun 2026)
6.77%

Overview

Symbol
NSE:FISCHER
Exchange
NSE
Currency
INR

What Fischer Medical Ventures Limited does

Based on the company's own presentations, annual report and earnings calls.

Fischer Medical Ventures designs and indigenously manufactures MRI systems (through subsidiary Time Medical International Ventures) and is expanding into CT scanners and X-ray devices, earning through equipment sales to hospitals, diagnostic chains and distributors in India and export markets. Its Preventive Healthcare arm, FlynnCare Health Innovation, sells AI-enabled health kiosks and cloud/tele-diagnosis platforms (ATLAS, MIDAS, Clinics 2.0, LIVE Dx) that screen for chronic disease at scale in schools, rural health units and community programs. The company also holds minority/distribution stakes in adjacent health-tech ventures (voice-AI mental-health diagnostics, regenerative skin technology, brain-imaging devices, AI drug discovery/nutraceuticals). It operates via a group of India, Singapore and Malaysia subsidiaries supporting domestic and Southeast Asia/MENA expansion.

Segments

  • Diagnostic Imaging (Radiology)
  • Preventive Healthcare
MRI manufacturing capacity (single shift)
80 machines/year
MRI manufacturing capacity (scalable, two shifts)
150-160 machines/year
MRI product line-up
5 models (PICA, MICA, QUIN, NEONA, NOVA)
Manufacturing facility
Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam — first Indian company CDSCO-recognised for indigenous MRI manufacturing
Health-kiosk screening coverage
60+ clinical vital-sign parameters per kiosk session
Corporate footprint
Subsidiaries/JVs in India, Singapore (FMV International Ventures, FMV Healthcare) and Malaysia
Headquarters Chennai, Tamil Nadu, India Company website

How the price took the results

close before → close after

Q2 FY26
−2.3%
7 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Fischer Medical Ventures Limited

Free account: one company. Everything above stays public.

Write why you follow Fischer Medical Ventures Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Fischer Medical Ventures Limited

Guides on how to read this kind of business and the numbers that matter.